PROCÉDÉ DE TRAITEMENT ET DE DOSAGE BIOLOGIQUE FAISANT APPEL À UN FACTEUR INHIBANT LA MIGRATION DES MACROPHAGES (MIF) COMME FACTEUR DÉPRESSEUR DU MYOCARDE D'ORIGINE CARDIAQUE
Board of Regents, The University of Texas System;Baxter International Inc.;Baxter Healthcare SA
发明人:
申请号：
EP16170803.7
公开号：
EP3078386A2
申请日:
2004.08.30
申请国别(地区):
EP
年份:
2016
代理人:
摘要：
An embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody； and at least on pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-CD74 antibody； and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody； a therapeutically effective amount of at least one anti-MIF antibody； and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction and identifying an MIF inhibitor.
